Azasetron hydrochloride

Cat. No.: HY-B0068

CAS No.: 123040-16-4

Molecular Formula: $C_{17}H_{21}Cl_2N_3O_3$

Molecular Weight: 386.27

Target: 5-HT Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: 4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H_2O : 20 mg/mL (51.78 mM; Need ultrasonic)

DMSO : 2.22 mg/mL (5.75 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.5889 mL	12.9443 mL	25.8886 mL
5 mM	0.5178 mL	2.5889 mL	5.1777 mL
10 mM	0.2589 mL	1.2944 mL	2.5889 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
   Solubility: 50 mg/mL (129.44 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Azasetron (Y-25130) hydrochloride, a benzamide derivative, is a potent and selective 5-HT3 receptor antagonist. Azasetron is used in the study for Chemotherapy-induced nausea and vomiting (CINV)[1].

IC_{50} & Target

5-HT_3 Receptor

0.33 nM (IC_{50})

In Vivo

Azasetron could effectively penetrate through the skin and pass into the systemic circulation[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Four male Bama miniature pigs weighing 9-11 kg (15-16 weeks old)[2].
Dosage:	0.5 mg/kg.

Administration:	I.V. administration via the abdominal vein.
Result:	The mean plasma concentration dropped to minimum at 36 h. C_{max} = 44.88 ± 7.16 ng/mL) was achieved at the time point of 66.00 ± 22.98 h (T_{max}).

CUSTOMER VALIDATION

- Protein Cell. 2019 Mar;10(3):178-195.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Sato, N., et al., Antagonistic activity of Y-25130 on 5-HT3 receptors. Jpn J Pharmacol, 1992. 59(4): p. 443-8.

[2]. Haga, K., et al., The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. Jpn J Pharmacol, 1993. 63(3): p. 377-83.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA